Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwCLL 2019 | Comparing CLL regimens with MRD

John Seymour, MBBS, PhD, Peter MacCallum Cancer Center, Melbourne, Australia, elaborates on the use of measurable residual disease (MRD) to compare the efficacy of chronic lymphocytic leukemia (CLL) treatment regimens. This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.